Dual TLR2 and TLR7 agonists as HIV latency-reversing agents

The presence of a reservoir of latently infected cells in HIV-infected patients is a major barrier towards finding a cure. One active cure strategy is to find latency-reversing agents that induce viral reactivation, thus leading to immune cell recognition and elimination of latently infected cells,...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:JCI Insight
Auteurs principaux: Macedo, Amanda B., Novis, Camille L., De Assis, Caroline M., Sorensen, Eric S., Moszczynski, Paula, Huang, Szu-han, Ren, Yanqin, Spivak, Adam M., Jones, R. Brad, Planelles, Vicente, Bosque, Alberto
Format: Artigo
Langue:Inglês
Publié: American Society for Clinical Investigation 2018
Sujets:
Research Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC6237480/
https://ncbi.nlm.nih.gov/pubmed/30282829
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/jci.insight.122673
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires